Innovation

GREENWOOD VILLAGE, Co and New York, NY — (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology. This trial is evaluating Nantheia™ A1002N5S for Opioid Sparing in the treatment of participants...

Read More

GREENWOOD VILLAGE, Colo. & LOS ANGELES , CA — (BUSINESS WIRE) - ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will...

Read More

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial. Pre-clinical and initial clinical studies show ANANDA’s...

Read More

GREENWOOD VILLAGE, Colo. & LOS ANGELES, CA (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid...

Read More

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD...

Read More

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a second clinical trial to evaluate the effect of cannabidiol in ANANDA’s proprietary delivery technology on opioid sparing in participants with chronic radiculopathic pain syndromes maintained on opioid therapy. An Investigational New Drug (IND) application has been approved by the U.S. Food...

Read More

GREENWOOD, Colo. & NEW YORK, January 12, 2021 - ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a new clinical trial evaluating the efficacy of cannabidiol in ANANDA’s proprietary delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with traumatic brain injury. An Investigational New Drug...

Read More

GREENWOOD, Colo., September 8, 2020 - ANANDA Scientific Inc., a biotech pharma company, today announced that Sohail Zaidi has been appointed as ANANDA’s new President. "Sohail Zaidi is already proving to be an extraordinary leader who has been flawlessly executing our pioneering clinical trial program, and we are thrilled to continue pursuing ANANDA’s strategic vision under his guidance," said Mark J. Rosenfeld, M.S., Ph.D., ANANDA Scientific’s Chief...

Read More

GREENWOOD, Colo., August 18, 2020 - ANANDA Scientific Inc., a biotech pharma company, today announced that John Suh, previously CEO of LegalZoom, has been appointed to ANANDA’s Board of Directors as its new Executive Director. "We are very pleased to welcome John as Executive Director of the ANANDA Board of Directors," said Mark J. Rosenfeld, M.S., Ph.D., ANANDA Scientific’s Chief Executive Officer. "John’s experience in growing successful...

Read More

GREENWOOD, Colo., April 1, 2020 (Newswire.com) - ANANDA Scientific, a biotech pharma company, today announced that its clinical research team will initiate trials to assess the company´s proprietary Liquid Structure™ Cannabidiol (CBD) formulation as a treatment for mitigating the impact of COVID-19 infections, specifically, the “cytokine storms” that result from an excessive production of immune system proteins and are a major cause of severe respiratory distress, other...

Read More